# Sellas Leukemia Vaccine Shows 9-Month Survival Benefit in Phase 3 Trial

Sellas Life Sciences has reported positive results from a phase 3 study of its cancer vaccine for acute myeloid leukemia (AML). The treatment produced a more than nine-month improvement in overall survival compared to standard care.

The vaccine, which targets a protein commonly found on AML cells, was tested in patients with a specific form of the blood cancer. The nine-month survival benefit represents the primary endpoint of the late-stage trial.

Sellas plans to discuss the data with regulatory authorities. The company has not yet announced a timeline for potential approval submissions.

**Context**

Cancer vaccines represent a growing area of biotech research. Unlike preventive vaccines, therapeutic vaccines are designed to train the immune system to recognize and attack existing cancer cells. AML is an aggressive leukemia with limited treatment options, especially for older patients or those who relapse after initial therapy. A vaccine that extends survival by nearly a year could shift the standard of care if approved. The field has seen several recent vaccine failures, making durable survival benefits in late-stage trials notable for the oncology community.

Source: [original report](https://www.fiercebiotech.com/biotech/sellas-marks-nine-month-survival-benefit-late-stage-leukemia-vaccine-study)